CTLA4 and glioblastoma: Modulation of human cytomegalovirus (CMV)-specific DCs, application of glioma stem cell-antigens-loaded DC vaccines, cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and PD-1 blockage, etc., are among the numerous extensive works (as reviewed in detail in [14,15]) that have been recently done and allowed for a clinical translation of glioblastoma immune targeting.